Performance of the eclipse monitor unit objective tool utilizing volumetric modulated arc therapy for rectal cancer.

AIM

To assess the performance of the monitor unit (MU) Objective tool in Eclipse treatment planning system (TPS) utilizing volumetric modulated arc therapy (VMAT) for rectal cancer.

BACKGROUND

Eclipse VMAT planning module includes a tool to control the number of MUs delivered: the MU Objective tool. This tool could be utilized to reduce the total number of MUs in rectal cancer treatments.

MATERIALS AND METHODS

20 rectal cancer patients were retrospectively studied using VMAT and the MU Objective tool. The baseline plan for each patient was selected as the one with no usage of the MU Objective tool. The number of MUs of this plan was set to be the reference number of MUs (MU). Five plans were re-optimized for each patient only varying the Max MU parameter. The selected values were 30%, 60%, 90%, 120% and 150% of MU for each patient. Differences with respect to the baseline plan were evaluated regarding MU number and parameters for PTVs coverage evaluation, PTVs homogeneity and OARs doses assessment. A two-tailed, paired-samples -test was used to quantify these differences.

RESULTS

Average relative differences in MU number obtained was 10% for Max MU values of 30% and 60% of MU, respectively ( < 0.03). PTVs coverage and homogeneity were not compromised and discrepancies obtained with respect to baseline plans were not significant. Furthermore, maximum OARs doses deviations were also not significant.

CONCLUSIONS

A 10% reduction in the MU number could be obtained without an alteration of PTV coverage and OARs doses for rectal cancer.